DiaSys Presents New Assays and Clinical Chemistry Analyzers at MEDICA 2022
Posted on 14 Nov 2022
DiaSys Diagnostic Systems GmbH (Holzheim, Germany) is presenting its new assays to determine HDL and LDL-cholesterol, alongside the respons®940, the new member of the company’s family of clinical chemistry analyzers, at MEDICA 2022. The MEDICA 2022 Trade Fair is being held in Düsseldorf, Germany from 14-17th November. More than 5,000 exhibitors from 70 countries are presenting their newest products and ideas at MEDICA which draws 120,000 trade visitors from over 170 countries every year.
At this year’s edition of MEDICA, DiaSys is exhibiting respons®910, a compact and fully-automated bench top clinical chemistry analyzer designed for maximum efficiency. Its high on-board capacity of 30 different methods in mono- or twin-containers and 30 sample positions offer the necessary flexibility for everyday use. The integrated STAT port allows easy loading of emergency samples at any time. The wide range of high-quality clinical chemistry and immunoturbidimetric tests manufactured by DiaSys rounds off the respons®910 system.
DiaSys is also presenting the HDL-c direct FS and LDL-c direct FS, its two innovative new reagents added to its cardiovascular risk assessment portfolio. Both are homogenous assays for direct determination and offer long calibration and onboard stability of up to four months. Combined with wide measuring ranges and good precision at clinical cut-off points, DiaSys assays HDL-c direct FS and LDL-c direct FS are of high value for clinical-chemistry laboratories.
Another highlight at the company’s booth at MEDICA 2022 is the presentation of Procalcitonin FS, an innovative, immunoturbidimetric assay to determine Procalcitonin that offers an excellent alternative to established methods. Procalcitonin FS offers a reliable alternative, when time matters in sepsis management. The fluid-stable, particle enhanced immunoturbidimetric assay is characterized by a good precision at clinical cut-off levels and high prozone security. Procalcitonin FS has good onboard and calibration stability and shows high tolerance to endogenous interferents and common therapeutics used in sepsis management. Additionally, the assay shows good concordance to established methods. Procalcitonin FS, dedicated kits are available for the DiaSys respons® systems and BioMajesty® JCA-BM6010/C.
Related Links:
DiaSys Diagnostic Systems
